Ublituximab Bests Teriflunomide in Relapsing Multiple Sclerosis

WEDNESDAY, Aug. 31, 2022 -- Patients with relapsing multiple sclerosis receiving ublituximab have lower annualized relapse rates and fewer brain lesions on magnetic resonance imaging than those receiving teriflunomide, according to a study published...